Moderna, BioNTech rise as vaccine advisory panel backs off mRNA vaccine threat
Source: SeekingAlpha
2026-03-11 15:24:26 ET
More on Moderna, BioNTech
- BioNTech SE 2025 Q4 - Results - Earnings Call Presentation
- BioNTech SE (BNTX) Q4 2025 Earnings Call Transcript
- Moderna: Pipeline Hope Won't Pay The Bills
- Biontech outlines €2B–€2.3B revenue target for 2026 while advancing late-stage oncology pipeline and leadership transition
- BioNTech falls on outlook, departure of co-founders
Read the full article on Seeking Alpha
For further details see:
Moderna, BioNTech rise as vaccine advisory panel backs off mRNA vaccine threat
BioNTech SE
NASDAQ: BNTX
BNTX Trading
2.05% G/L:
$90.21 Last:
289,767 Volume:
$89.78 Open:
BNTX Latest News
BNTX Stock Data
$26,377,590,776
95,508,380
N/A
104
N/A
Biotechnology & Life Sciences
Healthcare
DE
Mainz
